|
|||
2015-05-26 15:30:00 CEST 2015-05-26 15:30:56 CEST REGULATED INFORMATION Biotie Therapies - Total number of voting rights and capitalChange in the number of votes relating to Biotie Therapies Corp.'s sharesBIOTIE THERAPIES CORP. Stock Exchange Release 26 May 2015 at 4.30 p.m. Change in the number of votes relating to Biotie Therapies Corp.'s shares Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 17 December 2014, pursuant to the Stock Option Plan 2011 (the "Plan") as follows: Shares conveyed Cumulative shares conveyed Remaining shares to be since 17 December 2014 conveyed 237,500 2,447,375 0 Under the Stock Option Plan 2011, the owners of the stock options may subscribe for a maximum total of 7,401,000 new shares in the Company or existing shares held by the Company, of which a total of 1,844,250 were subscribed for in 2014. A total of 237,500 shares have been subscribed for during the period 6 May 2015 and 25 May 2015 and 237,500 of the treasury shares will be used for these share subscriptions. The subscription price of EUR 0.01 per share has been fully paid by the employee and the EUR 2,375 funds received will be credited to the Company's reserve for non-restricted equity. Due to share issues already made pursuant to the Stock Option Plan 2011, forfeitures and some of the instruments based on the plan having been left unallocated, a maximum of 1,957,500 shares may still be issued pursuant to the Stock Option Plan 2011. The conveyed shares previously held as treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows: Increase in number of Total amount of Number of the Total number outstanding shares voting rights Company's shares held of registered by the Group shares 237,500 453,227,734 2,740,440 455,968,174 Turku, 26 May 2015 Biotie Therapies Corp. Timo Veromaa, President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media [HUG#1923912] |
|||
|